.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

AJMC® in the Press, July 24, 2020

July 24, 2020

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care^® (AJMC^®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.

An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC^®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.